LKT Labs

Biochemicals for Life Science Research

BYL719

BYL719

Product ID B9700
Cas No. 1217486-61-7
Purity ≥99%, ≥99%ee
Product Unit SizeCostQuantityStock
1 mg $63.00 In stock
5 mg $115.50 In stock
25 mg $173.30 In stock
100 mg $446.30 In stock
Bulk Quote

Quicklinks

Description

BYL-719 is an ATP-competitive oral PI3K inhibitor selective for the p110α isoform that is activated by a mutant PIK3CA gene in HER2+ breast cancers and gastric cancers. BYL-719 exhibits anticancer chemotherapeutic activity and inhibits proliferation in a variety of cell lines. IGF1 and neuregulin 1 activate mTOR, a downstream target of PI3K that mediates resistance to BYL-719 in some in vitro cancer models. This compound also decreases invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer.

Product Info

Cas No.

1217486-61-7
Purity

≥99%, ≥99%ee
Formula

C19H22F3N5O2S
Formula Wt.

441.47
Chemical Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide
IUPAC Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide
Synonym

Alpelisib, NVP-BYL719, BYL-719
Solubility

DMSO 88 mg/mL (199.33 mM) Ethanol 2 mg/mL (4.53 mM) Water Insoluble
Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

B9700 MSDS PDF
Info Sheet

B9700 Info Sheet PDF

References

Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

Elkabets M, Vora S, Juric D, et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer. Sci Transl Med. 2013 Jul 31;5(196):196ra99. PMID: 23903756.

Abstract: Juric. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. American Association for Cancer Research. 2012.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • N0262

    Naphazoline Hydrochloride

    α1-adrenergic agonist.

    ≥97%
  • P0110

    (R)-P7C3-OMe

    Methoxy aminopropyl carbazole, neuroprotective....

    ≥98%
  • A1368

    Adrenomedullin (1-52), human

    Endogenous peptide hormone, involved in cell gr...

    ≥95%
  • T0299

    Tazobactam Sodium

    β-lactamase inhibitor.

    ≥98%
  • S7618

    StemRegenin 1 Hydrochloride

    AhR antagonist.

    ≥98%
  • A6269

    Apremilast

    PDE4 inhibitor.

    ≥98%
  • G1310

    GDC-0349

    mTOR inhibitor.

    ≥98%
  • C0375

    Ac-DEVD-pNA

    Caspase 3 substrate.

    ≥95%
  • Q8134

    Quinapril Hydrochloride

    ACE inhibitor.

    ≥98%
  • M3232

    Methylisoindigotin

    Indirubin derivative.

    ≥98%
  • P600006

    RP-6306

    PKMYT1 inhibitor

    ≥98%
  • T7034

    Trimethoprim

    Dihydrofolate reductase inhibitor.

    ≥98%
  • P6977

    Pyr-GR-pNA

    Fluorogenic substrate used to measure serine pr...

    ≥98%
  • A7462

    Aspartame

    Dipeptide ester, commercial sweetener.

    ≥98%
  • A4617

    Aloe Emodin

    Anthraquinone found in aloe; CTFR Cl- channel a...

    ≥98%
  • I527211

    Infigratinib Phosphate

    FGFR inhibitor.

    ≥98%
  • S8248

    Sulfamethoxazole

    Sulfonamide; PABA inhibitor.

    ≥98%
  • G4798

    Glycitein

    Aglycone isoflavone found in soy and red clover...

    ≥98%
  • N859614

    NVP-LDE225

    Smo inhibitor.

    ≥98%
  • M3309

    Miconazole

    Imidazole; 14-α demethylase inhibitor, potenti...

    ≥98%